Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our mission is to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
“The results provide the first placebo controlled evidence of efficacy for MYDICAR® and raised no safety concerns. These findings provide strong support for moving forward to Phase III studies using larger numbers of patients conducted over longer periods of time,” said Professor Barry H Greenberg, the presenter of the trial, from University of California San Diego. “MYDICAR® has the potential to change the treatment landscape for patients with severe heart failure by offering us a new tool in the box.”
New treatments, he added, are particularly needed for this group of patients who have yearly mortalities of 10 to 20%, or greater. “Current options for patients with severe heart failure include cardiac transplantation and left ventricular assist devices, both of which are expensive, can have problems associated with use and furthermore aren’t applicable to all patients.”
MYDICAR®, is a genetically targeted enzyme replacement therapy designed to restore levels of SERCA2a, an enzyme found in the myocardium that regulates calcium cycling and contractility. The heart’s ability to contract, and thus to pump blood and maintain oxygenation of the body, is determined by a continual re-loading of the sarcoplasmic reticulum with calcium ions. Studies have established clear associations between depleted SERCA2a enzymes in cardiac cells and progression of end stage heart failure. “As the heart begins to fail the SERCA2a levels get depressed, leading to a vicious cycle where the heart fails even more,” explained Greenberg.
With MYDICAR®, developed by CelladonCorporation (La Jolla, California), the SERCA2a gene is delivered using recombinant adeno-associated viral vector (AAV), a naturally occurring virus that approximately 90% of the population have been exposed to with no evidence of harm. MYDICAR® is provided in a single dose delivered directly into the coronary arteries during a short outpatient procedure, performed in a standard cardiac catheterization laboratory via a small incision in the upper leg. MYDICAR® is then carried to the heart muscle where it is taken up within the cells of the heart. Previous studies using reagents similar to MYDICAR® have shown delivery of the SERCA2a gene to skeletal muscle in humans results in persistence of gene activity for longer than four years.
The CUPID (Calcium Up-regulation by Percutaneous administration of gene therapy In cardiac Disease) trial enrolled 37 patients from 16 centres in the US with NYHA Class III and IV. Additional inclusion criteria included being aged 18 to 75 years, having ischemic or non-ischemic cardiomyopathy, maximal oxygen consumption of <20 mL/kg/min, left ventricular ejection fraction less than 35% and ICDs implanted. In the study, patients were randomised to placebo (N=14), low dose MYDICAR® (6x 10 11 DNase Resistant Particle, N=8); mid does MYDICAR(R) (3x10 12 DNase Resistant Particle, N=8) or high dose (1x10 13 DNase Resistant Particle,N=9) . All patients received standard treats including beta blockers, angiotensin converting enzyme inhibitors and diuretics.
Results of the primary analysis, undertaken after six months showed:
© 2017 European Society of Cardiology. All rights reserved